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Rheumatoid arthritis (RA) and osteoarthritis (OA) are the two most common joint diseases. Their clinical manifestations include pain, joint destruction and recurrent attacks, irreversible joint deformity and disability, which seriously affect patient's work ability and quality of life.
(1-5) Despite recent major advances of biologic therapies, many unmet clinical needs remain due to the refractory nature of RA and the lack of effective treatment for OA. (3, (6) (7) (8) In the past several years, we started to study the involvement of the lymphatic system in the pathogenesis of arthritis in mouse models of RA and OA. We found the existence of the lymphatic vasculature in joint soft tissues and named them the peri-articular lymphatic system. (9) We speculated that in normal joints the peri-articular lymphatic system drains fluid and macromolecules from synovial and interstitial space of these soft tissues to maintain the homeostasis of under pathological condition such as arthritis, it removes fluid containing catabolic factors and inflammatory cells from the synovial space and surrounding soft tissues to limit the progression of joint tissue damage. We established a protocol using a near-infraredindocyanine green (NIR-ICG) system to measure the draining function dynamically in mouse models of RA and OA. (9) (10) (11) (12) We demonstrated that the blockade of lymphangiogenesis and lymphatic drainage accelerates while stimulation of lymphatic function attenuates severity. (11, 12) These mouse data suggest a strong negative correlation between the histopathology and lymphatic drainage of arthritic joints: better lymphatic drainage, lesser tissue damage. We noticed the similarity between the dysfunction of lymphatic drainage in arthritic joints and "Bi" disease of Chinese medicine (CM), and demonstrated that several directly affect the function of lymphatic endothelial cells. Here we review advances about the interaction between joint inflammation and changes in the peri-articular lymphatic system and lymphatic dysfunction in arthritis.
Lymphatic Vasculature and the Peri-articular Lymphatic System
The lymphatic vasculature plays an important role in fluid homeostasis and transport of immune cells, inflammatory cytokines, and dietary lipids. It is composed of a network formed by primary capillaries and collecting vessels. Lymphatic endothelial cells (LECs) of capillaries present loose overlapping intercellular junctions and anchoring filaments that support fluid drainage. LECs specifically express proteins such as lymphatic endothelial hyaluronan receptor 1 (LYVE-1) (13) (14) (15) (16) and podoplanin, (17) (18) (19) which have been used as markers for identifying lymphatic vessels in tissue sections. The LEC junctions and permits interstitial fluid uptake when interstitial fluid accumulates within tissues, the extracellular matrix swells and pulls the anchoring filaments. Collecting vessels transport the lymph to the blood flow, while lymphatic smooth muscle cells (LSMCs) sequentially contract to propel lymph fl ow, and intra-luminal valves prevent lymph backfl ow.
One study determined lymphatic vessels in synovial tissue from 5 healthy persons by using immunohistochemistry (IHC) with anti-LYVE-1 antibody. In this study, LYVE-1 + lymphatic vessels were found at adipose, areolar, fi brous types of the normal synovial membrane, the deep subintima and underlying fibrous tissue of the joint capsule. (20) Another study examined lymphatic vessels in 60 normal synovium specimen using IHC with anti-podoplanin antibody and demonstrated that podoplanin + vessels are present in synovium, but are not in the subchondral bone area. (21) These studies did not separate lymphatic capillaries from mature vessels, which require staining staining the samples with anti-alpha smooth muscle actin (αSMA) antibody to identify LSMCs, a feature of mature vessels. Another limitation of these earlier studies is that regular IHC is not able to the distribution of lymphatic vasculature in an entire joint due to the rapid disappearance of IHC fl uorescence signals.
To examine the distribution of peri-articular lymphatic vessels in an entire knee, we observed podoplamin/αSMA double stained knee sections of C57BL/6J wild type mice under a whole-slide digital imaging system. Numerous podoplanin + lymphatic vessels were observed in the soft tissues around the knee joint and deep in the synovial membrane, the fat pad, the fi brous layer of the articular capsule, the articular ligaments, and the patellar tendon region. Lymphatic vessels were mainly localized in the fat pad near the meniscus in fibrous tissues adjacent to the synovial membrane and between ligament/tendon and bone. Consistent with human samples, no podoplanin + vessels were detected within the meniscus, articular cartilage, or subchondral bones. (22) We also observed podoplamin + /αSMA + mature lymphatic vessels in the above areas, but the numbers of mature vessels were much less than capillaries. Using NIR-ICG, we demonstrated in mice collecting lymphatic vessels afferent to the popliteal lymph node (PLN) drain ICG or dye injected into footpad, ankle joints, or surrounding soft tissues. (10) In contrast, collecting lymphatic vessels afferent to the iliac lymph nodes drain ICG or dye injected into knee joint space, which embedded deeply in the muscles and can not be seen by ICG-NIR. (23) 
Lymphangiogenesis in Arthritis
Several studies report that synovial specimens from RA patients have increased lymphatic vessel formation. In RA synovial tissues, a large number of synovial lining cells and stromal cells surrounding microvessels were observed to express vascular endothelial growth factor (VEGF)-C, a growth factor essential for LECs. (24) We and others reported that joint specimens from tumor necrosis factor (TNF) transgenic (TNF-Tg) and K/B×N arthritic mice have increased lymphatic vessel numbers and size compared with wild type control mice, (23) suggesting that inflammation triggers lymphangiogenesis in this disease. Furthermore, TNF stimulated VEGF-C expression of CD11b + /Gr-1 -/low osteoclast precursors through increasing nuclear factor kappaB (NF-κB) binding to an NF-κB sequence in the VEGF-C promoter, (23) and induce rheumatoid synoviocytes to express VEGF-C. (25) Different from RA patients, IHC for LYVE-1 or podoplanin expression in joint sections from OA patients are controversial, some increased (20) and some decreased (21, 22) numbers of lymphatic vessels.We speculated that the different distribution and alteration of lymphatic vessels in OA samples is due to variability of inflammation. We used mouse models of OA with meniscal-ligamentous injury or mice with conditional knockout of the gene for cartilage transforming growth factor (TGF) type Ⅱ receptor and stained joint sections with anti-podoplanin and α-SMA antibodies to identify blood vessels, capillary lymphatic vessels and collecting (mature) lymphatic vessels. We collected IHC images using whole-slide imaging system, and found that in normal joints, lymphatic vessels were distributed in soft tissues (mainly around the joint capsule, ligaments, fat pads, and muscles). In mild OA, the number of capillaries was significantly increased in joints of mice, while the number of collecting lymphatic vessels was markedly decreased with severe OA. (22) In addition, it was reported that VEGF-C protein was localized in synovial lining cells and endothelial cells in OA synovial tissues.
Thus, we concluded that the lymphatic system may play an important role in the pathogenesis of RA and OA that is worth for further investigation.
Establishment of A Lymphatic Imaging Protocol to Assess the Function of Colleting Lymphatic Vessels that Drain Fluid from Joints in Mouse Models of Arthritis
The role of the peri-articular lymphatic system in arthritis has not been well investigated because of inadequate imaging methods to assess lymphatic draining function in mouse models. In 2010, our group established an NIR-ICG lymphatic imaging protocol allows us to observe and assess lymphatic drainage from the ankle area or knee joint space of mice. To investigate the lymphatic drainage from ankle, we injected ICG subcutaneously into the footpad and performed NIR-ICG on the entire leg. We observed that ICG rapidly expanded around the injection site and reached the maximal within 30 min. At the same time, two collecting lymphatic vessels containing ICG were present, linking the ankle area to the upstream PLN. Thus, we could observe and record the ICG fl ow from the footpad to the PLN through the collecting lymphatic vessels, the ICG signaling intensity, and the time that it takes for ICG to reach the PLN and to be cleared from the footpad. These result in 5 outcome measures of draining function of lymphatic vessels collecting fluid from soft tissues surrounding ankle joints: (1) T-initial (T-in), the time that it takes for the ICG to be detected in vessels; (2) S-max, the maximum ICG signal intensity observed in the PLN; (3) T-max, the time it takes for a PLN to achieve maximal ICG signal intensity; (4) ICG clearance (%), an assessment of ICG wash out through the lymphatics and is quantified as the percent difference of ICG signal intensity between the two ICG-NIR images from the ROI of the PLNs or footpad at S-max (1st day) and 24-h post-ICG injection; and (5) pulse, which is the ICG pulses that pass the region of interest within 400 s. (10) To assess the draining function of lymphatic vessels from knee joints, we injected ICG into the synovial space of mouse knee joint, and visualized ICG fluorescence over the entire leg under NIR imaging system. In contrast to ankle lymphatic imaging, (10) bright lymphatic vessels could not be observed when ICG was injected into knee joints. Instead, we observed that the ICG signal in knees reached a peak after 30 min to 1 h and disappeared within 6 h. Thus, we developed two outcome measures of function of lymphatic vessels draining factors within the synovial space of knee: (1) T-max, the time that it takes to reach the maximum signal intensity in the injection site, and (2) ICG clearance, the percentage of ICG that has been removed from the injection site 3-6 h after the injection. (22) To determine where knee-injected ICG goes, we opened skin, dissected muscles, and found colleting lymphatic vessels containing ICG, linking knee to upstream ILNs. (26) Thus, it is likely that the collecting lymphatic vessels that drain knee joints, including synovial space and surrounding soft tissues, are present at deep tissues, which prevents them to be observed by ICG/NIR imagining.
Role of Lymphatic Drainage and Lymphangiogenesis in Mouse Models of Arthritis
After the development of NIR-ICG lymphatic imaging system, we wanted to investigate whether inflammatory-erosive arthritis affected lymphatic contraction in preclinical models. We fi rstly observed K/B×N mice, which developed increased lymphatic pulsing frequency and clearance during acute arthritis (1 month of age), and the lymphatic pulse and clearance of which returned to WT levels during the chronic phase (3 months of age).
(10) Simultaneously,
we tested the lymphatic function of a chronic infl ammatory arthritis model, TNF-Tg mice, and found that both lymphatic pulse and clearance decreased at 5 months of age. (12, 26, 27) Those studies suggested that there are two distinct lymphatic phenotypes that occur in inflammatory arthritis: increased lymphatic transport at an initial period, and reduced lymphatic drainage function at chronic phase. Thus we believe that lymphatic function plays an more important role in chronic infl ammatory arthritis.
OA is generally considered a degenerative joint disease affecting the aged population. Recent studies demonstrate that chronic infl ammation also contributes to OA pathogenesis. (23, 28, 29) To examine the lymphatic drainage in OA, we used meniscal-ligamentous injury (MLI)-induced knee OA mouse model, and examined the knee lymphatic draining function in mice 12 and 20 weeks post-MLI. We found markedly longer T-max and delayed clearance in OA knees at both time points, compared with sham-operated knees, and the alteration of T-max and clearance was in knees of mice 20 weeks post-MLI as compared with knees of mice 12 weeks post-MLI. This study demonstrated that lymphatic drainage decreased in OA knee joints.
To examine the effect of lymphatic draining function and lymphangiogenesis on inflammatory arthritis, we performed formal gain and loss of function studies in TNF-Tg mice. Because VEGF-C signaling through VEGFR-3 is the primary pathway for lymphangiogenesis, we treated TNF-Tg mice with VEGFR-3 neutralizing antibody to block the lymphangiogenesis for loss function study. We found that VEGFR-3 blockade increased joint synovial inflammation and focal bone and cartilage erosions, accompanied by decreased joint and PLN lymphangiogenesis and lymphatic clearance. (11) These fi ndings indicate that lymphatic drainage function and lymphangiogenesis is an important compensatory mechanism for regulating joint inflammation during chronic arthritis. In the gain of function studies, we injected recombinant VEGF-C into the ankle joints of TNF-Tg mice, and observed significant therapeutic efficacy, including decreased inflammatory synovial volume, and reduced bone erosion, cartilage loss and osteoclast numbers, (12) accompanied an increase in lymphatic clearance from the footpad. This study suggests that promoting lymphatic transport is a potential treatment target for infl ammatory arthritis.
We performed a similar loss of function experiment in OA mouse model. We treated mice that received MLI-induced knee OA surgery with VEGFR-3 neutralizing antibody or isotype IgG control for 8 weeks. The knee lymphatic drainage and knee tissue injury were examined. Similar to TNF-Tg mice, VEGFR-3 neutralizing antibody significantly delayed knee ICG clearance and increased the severity of cartilage loss, and OA histological scores, suggesting peri-articular lymphatic system in the pathogenesis of OA.
Measurement of Lymphatic Flow in Joints of Large Animals
The above mouse model data suggest a strong positive correlation between the histopathology and lymphatic drainage of arthritic joints: better lymphatic drainage, lesser tissue damage. However, if the peri-articular lymphatic system participates in the pathogenesis of human arthritis has not been well studied, partially due to a lack of sensitive and noninvasive lymphatic imaging modalities. Importantly, we do not know if we can use NIR-ICG to examine lymphatic drainage in human joints. We decided to establish a working protocol for NIR-ICG in large animals that would help us design protocols for use in humans. For this, we examined the lymphatic drainage from ankle and knee joints of adult ovine using the NIR-ICG.
To examine the lymphatic vessels efferent from the ankle joint, we injected 100 μL ICG solutions at 1 mg/mL to the right ankle joints from the lateral site of both animals and observed the distribution and location of ICG using our NIR imaging system. At 10 min post-ICG injection, we started to observe lymphatic vessels that gradually become more obvious with time. At 30 min, we could clearly observe 2 lymphatic vessels efferent from the ankle joint, through the calf, and reach popliteal fossa (Figure 1 ). However, we could not observe ICG accumulation in popliteal lymph nodes as we have seen in mice. (10, 26) To observe the lymphatic vessels efferent from the knee joint, we injected 400 μL ICG solution into the right knee joint from the lateral site of the female ovine and into the knee joint from the left medial site of the male ovine. Compared with the easily identifi ed lymphatic vessels efferent from the ankle joint, we only observed one lymphatic vessel from a total of 3 knee joints that received ICG injection (Figure 2 ). The appearance of this lymphatic vessel did not last very long, and it seemed to go to deeper tissue after 30 min.
To examine the lymphatic draining function of the peri-articular lymphatic system of joints, we wanted to determine if we could set up a protocol to measure the ICG clearance of ovine knee joint. We are deeply embedded in the thick fat at the popliteal space and are clearly visible under NIR imaging. The length of the vessels from the ankle joint to PLN is about 21 cm (Figure 6 ). Because the PLN is embedded within fat tissue at the popliteal space, it could not be detected under NIR imaging without dissection.
In summary, we found that (1) NIR-ICG could detect two lymphatic vessels distal the ankle and toward the PLNs and lymphatic, if ICG was injected into soft tissues surrounding joints, but not if ICG was directly injected into ankle joint space; (2) NIR-ICG could measure ICG clearance after it was injected into ankle or knee joint space; (3) NIR-ICG could not detect lymphatic vessels that drain the knee joints because these vessels are embedded deeply in soft fat tissues. Based on these findings, we concluded that in large animals perhaps including in human subjects, NIR-ICG could be used to examine draining function of lymphatic vessels that drain fluid from soft tissues surrounding joints, but not synovial space could be used to assess the ICG clearance of joints, indirect measure of function of the peri-articular lymphatic system.
Lymphatic Drainage Function, Arthritis and "Bi" Theory of CM
Both RA and OA belong to "Bi" disease according to the CM theory. "Bi" disease refers to factors, including wind, cold, wet or hot, that invade human body to cause an obstruction of the circulation of qi and blood under the deficiency of vital qi. The main clinical manifestations of "Bi" disease are pain, numbness, heavy or inconvenient flexion at muscles, bones, tendons, or joints, or hot joint. These clinical symptoms are similar to those of arthritis.Interestingly, our findings of lymphatic dysfunction in arthritis are consistent with the theory of "Bi" because both of them involve "blockage", the former is lymphatic drainage while the latter is qi and blood. More importantly,
Figure 1. Lymphatic Vessel Efferent from the Ovine Ankle Joint
Notes: ICG solution (1 mg/mL in 400 mL) was injected into the ankle joint from the lateral site and followed by massaging the injection site to enhance lymphatic fl ow. NIR imaging was applied over the entire leg to determine the path of injected ICG via lymphatic vessels. NIR images illustrated the movement of ICG along the lymphatic vessels from the ankle joint (A), through the leg (B and C) to the popliteal space (D). 
Figure 2. Lymphatic Vessel Efferent from the Ovine Knee Joint
Notes: ICG solution (1 mg/mL in 400 mL) was injected into the knee joint from the lateral site followed by massaging the injection site to enhance lymphatic flow. NIR imaging was applied over the entire upper leg to determine the path of injected ICG via lymphatic vessels. NIR images illustrated the movement of ICG along a lymphatic vessel from the knee joint.
fi rst examined the ICG signal intensity at 30 min, 3, 6 and 24 h after ICG injection into the knee joint with a fixed NIR exposure time (50 ms). We found that the area positive for ICG signal at the inject site gradually increased from 30 min, peaked at 24 h and declined thereafter (Figure 3) . Under 50-ms NIR exposure time, the clearance at joints was 54%±9% at 48 h, 78%±12% at 72 h, and 86%±6% at 96 h (Figure 4) . The lymphatic pulses in lymphatic vessels efferent from ovine ankle joints were about 1.6±0.5 pulse/min ( Figure 5 ), similar to mice.
To confirm that ICG is transferred by lymphatic vessels after it has been injected into a joint space, we injected ICG and Evans' blue dye in the ankle joint, opened the skin and dissected the Evans' blue dye positive stained lymphatic vessel under NIRimaging. We found that both ICG and Evans' blue dye are transferred through two parallel lymphatic vessels efferent from the ankle joint. These lymphatic vessels Injection site
Lymphatic vessel
Lymphatic pulse several CM herbs that are dispelling "Bi" have been successfully used to treat a subset of arthritic patients who are also diagnosed as qi and blood obstruction in clinical practice. (30) (31) (32) However, if these CM herbs affect lymphatic vessel function as a new mechanism of action is not known.
Based on the similarity of "Bi" disease and lymphatic dysfunction in arthritis, e.g. the blockage theory and joint swelling/pain symptoms, we hypothesize that CM herbs that have dispelling "Bi" may improve lymphatic vessel function, thereby releasing "Bi" diseaseassociated blockade.
To this end, we tested Chinese herbal compounds [Duhuo Jisheng Decoction (独活寄生 汤), Juanbi Decoction (蠲痹汤) and Niubangzi Decoction Plus (加味牛蒡子汤)] and extracts (ferulic acid and Panax notoginseng saponins) in TNF-Tg mice, the mouse model that we have used in our arthritislymphatic research as described above. Both CM herbal compounds and extracts reduced joint tissue disease of these mice, including inflammation, bone and cartilage erosion. More importantly, they also promoted lymphatic drainage from affected joints to upstream lymph nodes (manuscript in preparation). Using a zebra fi sh reporter system, we found that Duhuo Jisheng Decoction, Juanbi Decoction, ferulic acid and Panax notoginseng saponins increased lymphatic thoracic duct formation. Those fi ndings suggest that the CM herbs that have dispelling "Bi" activity could improve lymphatic draining function, which may present a novel view to explain "Bi" theory in the pathogenesis and treatment of arthritis.
Concluding Remarks
Because lymphatic function and arthritis is a relative new field of study, there are many unsolved questions. For instance, we do not know if impaired lymphatic drainage occurs in RA and OA patients, if drugs that improve lymphatic draining function could relieve the inflammation or vice visa, how the drugs affect the lymphatic transport function or lymphangiogenesis. More importantly, we do not know if other "Bi" disease-treated drugs also affect lymphatic vessel function and the mechanisms involved. Answering these questions will enhance our understanding of the role of lymphatic vasculature in arthritis pathogenesis, may lead to a novel therapy for RA and OA by regulating LECs and LSMCs. It will also provide cellular and molecular mechanisms for "Bi" disease-treated drugs in the treatment of patients with "Bi" symptoms. 
